Whilst the majority of breast cancers are positive for estrogen receptor (ER+), progesterone receptor (PR+) and/or human epidermal growth factor receptor 2 (HER2+), and can thus be treated with targeted endocrine therapy2, a small subset of breast cancers are negative for all three receptors. This evidence concerns the gene PGR and breast carcinoma.